ABC Family Arquivos Brasileiros de Cardiologia International Journal of Cardiovascular Sciences ABC Heart Failure & Cardiomyopathy ABC Imagem Cardiovascular
Português English
ABC Family
Português English
  • About
    • About ABC Family
    • Internal Regulation
    • Editorial Board
    • Brazilian Society of Cardiology (SBC)
  • Issues
  • SBC Guidelines
  • Content
    • Videos
    • Podcasts
    • News
  • About
    • About ABC Family
    • Internal Regulation
    • Editorial Board
    • Brazilian Society of Cardiology (SBC)
  • Issues
  • SBC Guidelines
  • Content
    • Videos
    • Podcasts
    • News

ABC Family

  • ABC Family
  • Arquivos Brasileiros de Cardiologia
  • International Journal of Cardiovascular Sciences
  • ABC Heart Failure & Cardiomyopathy
  • ABC Imagem Cardiovascular
Search in

No content found.

Journals
Ordering
Article types
Others

  1. Home
  2. Keyword: Drug Therapy/adverse effects
ABC
Editorial

Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines

Aurora Felice Castro Issa

Anthracyclines are important components of many chemotherapy regimens for various solid and hematologic malignancies, including breast, gynecologic, and bladder cancers, as well as leukemia and lymphoma. Unfortunately, they are associated with a recognized risk of cardiotoxicity. Drugs in this class include doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin. The available evidence suggests that anthracycline-induced injury to the heart occurs during exposure and evolves over time.

Cancer therapy-related cardiac dysfunction (CTRCD), the classic cardiotoxicity associated with anthracyclines, is a serious adverse event that leads to interruption of cancer treatment, potentially severe heart failure (HF), and even death. Early identification of cancer therapy-related cardiac dysfunction is essential as it allows for early implementation of medical HF therapy.

[…]

  • Anthracyclines/therapeutic use
  • Biomarkers Pharmacological/dosage
  • Drug Therapy/adverse effects
  • Neoplasms
Read Full Article
Creative Commons Attribution (CC BY) Creative Commons license
04/03/2024 DOI: 10.36660/abc.20230821 Views 1
Figure 1
ABC
Review Article

Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?

Ricardo Stein et al. Thaís Beuren Luis Ramudo Cela Filipe Ferrari

Introduction, the DNA and the Genes

Pharmacogenomics (PGx) is the science of understanding the interaction between genes and drugs. The analysis of specific areas of the DNA provides information about a certain drug metabolism and about the expected response to a certain treatment. PGx also aims to reduce the incidence of adverse drug events (ADEs)., Many studies in this area have focused on the identification of genes that predispose to diseases, modulate drug response, affect drug concentration and correlate with adverse effects of patients exposed to different types of drugs, so the desired therapeutic benefit is achieved.

The causes of individual responses to a same drug dosage include age, genetic and immunological factors, comorbidities and interaction between active principles. Genetic variability may influence not only pharmacodynamics, but also pharmacokinetics, which studies the relationship of the absorption, metabolism and excretion of the drug to its systemic concentration.

[…]

  • Biotransformation
  • Cardiovascular Diseases
  • Drug Therapy/adverse effects
  • Genes
  • Genetic Profile
  • Genome
  • Heredity
  • Pharmacogenetics
  • Public Health
Read Full Article
Creative Commons Attribution (CC BY) Creative Commons license
23/10/2020 DOI: 10.36660/abc.20200151 Views 1

How to cite this article

EndNote RIS

Electronic Document Format (Vancouver)

Issa AFC. Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines. Arquivos Brasileiros de Cardiologia 2024;120(12):e20230821.

Electronic Document Format (ABNT)

Issa, Aurora Felice Castro. Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines. Arquivos Brasileiros de Cardiologia, v. 120, n. 12, e20230821, Mar. 2024.

Electronic Document Format (APA)

Issa, A. F. C. (2024). Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines. Arquivos Brasileiros de Cardiologia, 120(12), e20230821.

Electronic Document Format (ISO)

Issa, Aurora Felice Castro. Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines. Arquivos Brasileiros de Cardiologia [online]. 2024, vol. 120, n. 12, [cited 2026-10-14], e20230821. Available from: <https://journals.cardiol.br/en/article/biomarkers-in-the-evaluation-of-patients-undergoing-chemotherapy-with-anthracyclines/>. ISSN 0066-782X

EndNote RIS

Electronic Document Format (Vancouver)

Stein R, Beuren T, Cela LR, Ferrari F. Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?. Arquivos Brasileiros de Cardiologia 2020;115(4):690-70.

Electronic Document Format (ABNT)

Stein, Ricardo; Beuren, Thaís; Cela, Luis Ramudo; Ferrari, Filipe. Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?. Arquivos Brasileiros de Cardiologia, v. 115, n. 4, p. 690-700, Oct. 2020.

Electronic Document Format (APA)

Stein, R., Beuren, T., Cela, L. R., & Ferrari, F. (2020). Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?. Arquivos Brasileiros de Cardiologia, 115(4), 690-700.

Electronic Document Format (ISO)

Stein, Ricardo and Beuren, Thaís and Cela, Luis Ramudo and Ferrari, Filipe. Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?. Arquivos Brasileiros de Cardiologia [online]. 2020, vol. 115, n. 4, [cited 2026-10-14], pp. 690-700. Available from: <https://journals.cardiol.br/en/article/pharmacogenomics-and-cardiovascular-disease-where-are-we-and-where-do-we-go-from-here/>. ISSN 0066-782X

  • About ABC Family
  • Internal Regulation
  • Editorial Board
  • Brazilian Society of Cardiology (SBC)

Issues

SBC Guidelines

  • Videos
  • Podcasts
  • News